1. Market Research
  2. > All Companies
  3. > Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile

Summary

Rosetta Genomics, Ltd. (RGL) is a biotechnology company that discovers, develops and commercializes next generation diagnostic tests for personalized medicine. The company provides testing services such as rosetta cancer origin test, resetta lung cancer test, rosetta kidney cancer test and rosetta mesothelioma test. It is developing tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company has presence in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 7
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2009 to YTD 2015 8
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2009 to YTD 2015 9
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2009 to YTD 2015 10
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2009 to YTD 2015 11
Rosetta Genomics, Ltd., Medical Equipment, Deal Details 14
Partnerships 14
Rosetta Genomics Terminates Licensing Agreement With Avatao Biotech 14
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 15
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 16
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 17
Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 18
Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 19
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 20
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 21
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 22
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 23
Rosetta Genomics Expands Distribution Agreement With Genekor 24
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 25
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 27
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 28
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 29
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 31
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 32
Rosetta Genomics Enters Into Distribution Agreement With Genekor 33
Rosetta Genomics Enters Into An Agreement With Genetic Technologies 34
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs 35
Warnex Signs Distribution Agreement With Rosetta Genomics 36
Teva Pharma Enters Into An Agreement With Rosetta Genomics 37
Rosetta Genomics Terminates Its Licensing Agreement With Prometheus Labs 38
Prometheus Labs Signs An Agreement With Rosetta Genomics 39
Equity Offering 40
Rosetta Genomics to Raise USD8 Million in Private Placement of Units 40
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 42
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 43
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 45
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 47
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 48
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 49
Rosetta Genomics Completes Private Placement For US$2.7 Million 51
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 53
Rosetta Genomics Completes Private Placement For US$2.5 Million 55
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 57
Rosetta Genomics Completes Private Placement Of US$8 Million 59
Debt Offering 60
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 60
Acquisition 61
Rosetta Genomics Acquires PersonalizeDx from Prelude 61
Rosetta Genomics, Ltd. - Key Competitors 62
Key Employees 63
Locations And Subsidiaries 64
Head Office 64
Other Locations and Subsidiaries 64
Recent Developments 65
Strategy And Business Planning 65
Sep 02, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics 65
Feb 18, 2014: Rosetta Genomics Executes Agreement With MultiPlan 66
Financial Announcements 67
Mar 16, 2015: Rosetta Genomics Reports 2014 Financial Results 67
Sep 17, 2014: Rosetta Genomics Reports Financial Results for the First Half of 2014 69
Mar 31, 2014: Rosetta Genomics Reports 2013 Financial Results 71
Corporate Communications 73
Aug 18, 2014: Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice President of Sales and Marketing 73
Feb 18, 2014: Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care 74
Product News 75
May 12, 2015: Data on Rosetta Genomics' Novel Thyroid Nodule Classification Assay to be Presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress 75
Mar 26, 2015: Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test 76
Feb 26, 2015: Rosetta Genomics Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of Development 77
Jan 20, 2015: Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test Published in the Journal of Kidney Cancer 78
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test 79
Jul 10, 2014: Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer 80
Jun 09, 2014: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic 81
Product Approvals 82
Jul 22, 2014: Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test 82
Other Significant Developments 83
Jun 16, 2015: Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
Rosetta Genomics, Ltd., Medical Equipment, Key Facts, 2014 1
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2009 to YTD 2015 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 7
Rosetta Genomics, Ltd., Medical Equipment Deals By Type, 2009 to YTD 2015 8
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2009 to YTD 2015 9
Rosetta Genomics, Ltd., Deals By Market, 2009 to YTD 2015 10
Rosetta Genomics, Ltd., Medical Equipment, Deals Summary, 2009 to YTD 2015 11
Rosetta Genomics Terminates Licensing Agreement With Avatao Biotech 14
Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 15
Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 16
Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 17
Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 18
Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 19
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 20
Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 21
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 22
Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 23
Rosetta Genomics Expands Distribution Agreement With Genekor 24
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 25
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics 27
Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 28
Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 29
Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 31
Rosetta Genomics Enters Into Agreement With Carmel Medical Center 32
Rosetta Genomics Enters Into Distribution Agreement With Genekor 33
Rosetta Genomics Enters Into An Agreement With Genetic Technologies 34
Rosetta Genomics Enters Into Distribution Agreement With Super Religare Labs 35
Warnex Signs Distribution Agreement With Rosetta Genomics 36
Teva Pharma Enters Into An Agreement With Rosetta Genomics 37
Rosetta Genomics Terminates Its Licensing Agreement With Prometheus Labs 38
Prometheus Labs Signs An Agreement With Rosetta Genomics 39
Rosetta Genomics to Raise USD8 Million in Private Placement of Units 40
Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To US$75 Million 42
Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For US$4 Million 43
Rosetta Genomics Completes Private Placement Of Shares For US$6.6 Million 45
Rosetta Genomics Completes Private Placement Of Shares For US$2 Million 47
Rosetta Genomics Completes Private Placement Of Shares For US$1.4 Million 48
Rosetta Genomics Completes Private Placement Of Common Stock For US$1.5 Million 49
Rosetta Genomics Completes Private Placement For US$2.7 Million 51
Rosetta Genomics Completes Registered Direct Offering For US$3.3 Million 53
Rosetta Genomics Completes Private Placement For US$2.5 Million 55
Rosetta Genomics Completes Registered Direct Offering Of Shares For US$5.1 Million 57
Rosetta Genomics Completes Private Placement Of US$8 Million 59
Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For US$1.75 Million 60
Rosetta Genomics Acquires PersonalizeDx from Prelude 61
Rosetta Genomics, Ltd., Key Competitors 62
Rosetta Genomics, Ltd., Key Employees 63
Rosetta Genomics, Ltd., Other Locations 64
Rosetta Genomics, Ltd., Subsidiaries 64

List of Figures
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2009 to YTD 2015 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2009 to YTD 2015 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Market, 2009 to YTD 2015 1
Rosetta Genomics, Ltd., Medical Equipment, Deals By Year, 2009 to YTD 2015 7
Rosetta Genomics, Ltd., Medical Equipment, Deals by Type, 2009 to YTD 2015 8
Rosetta Genomics, Ltd., Medical Equipment, Deals By Region, 2009 to YTD 2015 9
Rosetta Genomics, Ltd., Medical Equipment, Deals by Market, 2009 to YTD 2015 10

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
CLC bio – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

CLC bio – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • November 2015
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Scarab Genomics, LLC – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Scarab Genomics, LLC – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • November 2015
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

Oryzon Genomics S.A. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Oryzon Genomics S.A. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • November 2015
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.